Adocia - ADOCY STOCK NEWS

Adocia, a clinical-stage biopharmaceutical firm focused on diabetes treatment, will announce its H1 2022 results on September 19, 2022, after market closure. A webinar led by key executives, including CEO Gérard Soula, is scheduled for September 20, 2022, at 6:00 p.m. CEST to discuss the results and program updates. Interested parties can register for the session and submit questions in advance. Adocia specializes in innovative therapies for metabolic diseases and holds over 25 patent families in its portfolio.

Adocia has successfully demonstrated the potential of its AdoShell Islets technology in achieving glycemic control in immunocompetent diabetic rats over a 132-day trial without insulin or immunosuppression. This groundbreaking study showcases the viability of AdoShell Islets for treating type 1 diabetes, especially for 'brittle' patients who experience unstable diabetes. Furthermore, ongoing trials confirm the technology's effectiveness, with diabetic rats showing weight gain and maintained glycemia. Results will be presented at the upcoming PODD 2022 conference in Boston.

Adocia (Euronext: ADOC) reported a strong financial performance for the first half of 2022, achieving revenues of €7.3 million, a significant increase from €0.4 million in the same period last year. The surge in revenue was propelled by a $5 million milestone payment from Tonghua Dongbao, following the first patient dosing in a Phase 3 study in China. Additionally, the cash position strengthened to €23.9 million, bolstered by the sale of a building and another milestone payment. However, operating cash consumption increased to €10.2 million, up from €7.4 million, indicating rising operational costs.

Adocia, listed on Euronext Paris under the ticker ADOCY, reported key updates regarding its liquidity agreement with Kepler Capital Markets. As of June 30, 2022, the liquidity account held 32,721 shares and a cash balance of €98,519.91. For the first half of 2022, the company bought 80,014 shares for €443,321.21 and sold 87,109 shares for €476,728.77. The liquidity agreement adheres to the AMF Decision n° 2021-01, highlighting Adocia's ongoing market practices.

Adocia, a clinical-stage biopharmaceutical company based in Lyon, France, has released its Letter to Shareholders for the first semester of 2022. Focused on innovative solutions for diabetes and metabolic diseases, Adocia is advancing through its proprietary technologies, including BioChaperone, AdOral, and AdoShell Islets, and holds over 25 patent families. The next financial update is scheduled for August 24, 2022. Investors should note the potential risks associated with the company's forward-looking statements, including uncertainties related to research and development.

Adocia has announced positive top-line results from a Phase 2 trial of M1Pram, a combination of insulin and pramlintide, showing significant weight loss compared to Humalog in Type 1 Diabetes patients. Participants lost an average of 2.13 kg over four months, with 82.4% reporting improved appetite control. The treatment maintained glycemic control and had a favorable safety profile, with adverse events primarily gastrointestinal. Adocia aims to partner for further development following these encouraging results.